609 Stock Overview A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
ABIONYX Pharma SA Competitors Price History & Performance
Summary of share price highs, lows and changes for ABIONYX Pharma Historical stock prices Current Share Price €1.23 52 Week High €1.28 52 Week Low €0.95 Beta 0.035 1 Month Change -3.90% 3 Month Change n/a 1 Year Change n/a 3 Year Change -47.35% 5 Year Change 311.35% Change since IPO -57.52%
Recent News & Updates
Less than half of directors are independent Dec 13
ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week Oct 25
Insufficient new directors Oct 01
Insufficient new directors Jun 24
ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis Jun 15
ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024 May 25 See more updates
Less than half of directors are independent Dec 13
ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week Oct 25
Insufficient new directors Oct 01
Insufficient new directors Jun 24
ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis Jun 15
ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024 May 25
ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024 May 18
Insufficient new directors Apr 12
New minor risk - Revenue size Mar 18
Full year 2023 earnings released Mar 11 ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024
New minor risk - Shareholder dilution Mar 05
Insufficient new directors Mar 05
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112 Feb 16
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D Jan 09
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023 Nov 25
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I Nov 21
Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week" Nov 03
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week" Oct 16
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess Jul 27
ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe Jul 12
ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe Jul 11
ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023 May 25
ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023 May 19
ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess May 11
Insufficient new directors Apr 24
ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial Jan 17 ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023
Insufficient new directors Jan 03
ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury Oct 05
ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury Apr 07 ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease Mar 30
ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022
ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease Jan 05
ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury Jun 08
Investor sentiment improved over the past week Jun 01
Investor sentiment improved over the past week Apr 29
Investor sentiment improved over the past week Mar 30
ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine Mar 03
New 90-day high: €1.24 Mar 02
Investor sentiment improved over the past week Mar 02 ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021
ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury Dec 24
ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease Dec 17
New 90-day high: €1.05 Nov 26
ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease Nov 26
New 90-day low: €0.68 Oct 29
ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors Oct 03
New 90-day low: €0.71 Sep 26
New 90-day low - €0.71 Aug 03 Shareholder Returns 609 DE Biotechs DE Market 7D 0% 1.1% -0.2% 1Y n/a -14.5% 7.0%
See full shareholder returns
Return vs Market: Insufficient data to determine how 609 performed against the German Market .
Price Volatility Is 609's price volatile compared to industry and market? 609 volatility 609 Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.7% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 609's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 609's volatility change over the past year.
About the Company Founded Employees CEO Website 2005 61 Cyrille Tupin abionyx.com
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
Show more ABIONYX Pharma SA Fundamentals Summary How do ABIONYX Pharma's earnings and revenue compare to its market cap? 609 fundamental statistics Market cap €42.17m Earnings (TTM ) -€3.36m Revenue (TTM ) €4.86m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 609 income statement (TTM ) Revenue €4.86m Cost of Revenue €3.92m Gross Profit €932.00k Other Expenses €4.29m Earnings -€3.36m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.097 Gross Margin 19.19% Net Profit Margin -69.15% Debt/Equity Ratio 14.4%
How did 609 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/27 01:22 End of Day Share Price 2024/12/11 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ABIONYX Pharma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Fanny Meindre CIC Market Solutions (ESN) Stephanie Lefebvre Gilbert Dupont Jamila El Bougrini Gilbert Dupont
Show 1 more analysts 
